Different patterns of inflammatory and angiogenic factors are associated with peritoneal small solute transport and peritoneal protein clearance in peritoneal dialysis patients

Yuanyuan Shi, Hao Yan, Jiangzi Yuan, He Zhang, Jiaying Huang, Zhaohui Ni, Jiaqi Qian and Wei Fang

Abstract

Background: Both peritoneal small solute transport and peritoneal protein clearance are closely linked to outcomes in peritoneal dialysis (PD) patients. However, the associated factors of these two components are not fully understood so far. This study aimed to investigate the association between a panel of systemic and peritoneal inflammatory and angiogenic factors and peritoneal solute transport properties.

Methods: Stable PD patients in PD center of Renji Hospital, School of Medicine, Shanghai Jiao Tong University were enrolled in present study. Serum and overnight effluent markers including angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), sTie-2, VEGF, IL-6 and IL-10 were determined. Mass transfer area coefficient of creatinine (MTACcr) and peritoneal protein clearance (Prcl) were calculated. Multivariable linear regression was used to examine the association between these markers and MTACcr as well as Prcl.

Results: A total of 320 patients were enrolled in present study, which consisted of 166 (51.9%) males with a mean age of 56.8 ± 14.2 years and a median PD duration of 32.5 (9.0–56.3) months. Multiple regression analyses showed that BSA, history glucose exposure, dialysate IL-6 AR and dialysate Ang-1 AR were independent associated factors of MTACcr, while BSA and serum Ang-1 were independent associated factors of Prcl.

Conclusions: MTACcr representing peritoneal small-solute transport and Prcl representing peritoneal large molecular transport are associated with slightly different panels of inflammatory and angiogenic factors.

Keywords: Angiogenic factors, Inflammatory factors, Peritoneal small solute transport, Peritoneal protein clearance, Peritoneal dialysis

Background

Peritoneal dialysis (PD) is a well-established renal replacement therapy for patients with end stage renal disease (ESRD) [1]. During long-term PD treatment, however, the peritoneal membrane undergoes functional as well as structural alterations, which may be the consequence of many causes such as peritonitis and continuous exposure to bioincompatible dialysis solutions with high concentrations of glucose and glucose degradation products, low pH as well as high osmolality etc. [2].

The most common functional alteration during long-term PD is increased peritoneal small-solute transport rate measured by dialysate-to-plasma (D/P) ratios or mass transfer area coefficients (MTAC) [3, 4], which is the major contributor to impaired ultrafiltration and ultimately discontinuation of treatment [5]. It has been well appreciated that high D/Pcr represented an independent risk factor for mortality and technique failure in PD patients [6–8] as a consequence of increased glucose
absorption from peritoneal cavity and inadequate dialysis, leading to suboptimal ultrafiltration capacities, fluid overload and malnutrition [9]. On the other hand, patients may lose approximately 5 g total protein or 4 g albumin daily from the peritoneal cavity during PD therapy [10]. Accumulating studies have suggested that peritoneal protein clearance (PrCl) was linked to poor outcomes in PD patients. These studies postulated that PrCl was associated with a higher prevalence of peripheral arterial disease [11], cardiovascular events [12], peritonitis [13], and increased mortality in PD patients [14]. So both peritoneal small solute transport and peritoneal protein clearance are closely linked to outcomes in PD patients.

Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) are antagonistic ligands of the TEK tyrosine kinase-2 (Tie-2) receptor [15]. It has been shown that Ang-1 was a strong anti-permeability factor that decreased vascular permeability and protected the adult vasculature against plasma leakage [16–18]. Experimental overexpression of Ang-1 during sepsis could reduce mortality through preservation of vessel integrity [19]. In contrast, increased circulating Ang-2 has been reported in various diseases with endothelial activation [20–22]. Additionally, vascular endothelial growth factor (VEGF) might inhibit vascular stabilization in an angiopoietin-dependent manner [23].

Despite both peritoneal small solute transport and peritoneal protein clearance were closely linked to outcomes in PD patients, the associated factors of these two components still remained unclear. Therefore, this study was designed to investigate the possible associated factors of peritoneal small-solute and large-molecular transport in patients undergoing PD.

Methods
Ethics statement
The study protocol was approved by the Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China (number: [2013] N022; year: January/2014). Written consent was given by the patients for their information to be stored in the hospital database and used for research.

Patient population
All clinically stable CAPD patients during April 1, 2014 to May 31, 2015 in PD center of Renji Hospital, School of Medicine, Shanghai Jiao Tong University were included in present study. Exclusion criteria included: (1) presence of systemic inflammatory disease, peritonitis or fluid overload within 3 months prior to the study; (2) malignancy; (3) taking glucocorticoid or immunosuppressive agents during the past 1 year; and (4) acute cardiocerebrovascular events that occurred within 3 months prior to the study. All patients were dialyzed with glucose-based peritoneal dialysis fluid (Dianeal®, Baxter). All enrolled patients were asked to come to PD center to take a standard peritoneal equilibration test. Our PD nurses performed the PET and obtained blood and effluent samples strictly according to the study procedure, so there was no missing data.

Protocol
The following demographic characteristics were collected at the enrollment of study: age, gender, height, weight, underlying cause of ESRD, date of PD initiation, previous peritonitis episodes, taking Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker (ACEI/ARB) or not, presence of comorbid diseases such as diabetes mellitus (DM) and cardiovascular disease (CVD). CVD was defined as a previous history of coronary artery disease, peripheral vascular disease or cerebrovascular disease. The historical dialysis regimen was collected to calculate the amount of historical glucose exposure according to Davies et al. [24].

On the night prior to PD center visit, the patient was asked to perform a dialysis exchange using his or her usual overnight dialysis regimen, and the overnight effluent was fully drained the next morning in the PD center. We weighed the bag of drained effluent to assess the volume, and the dwell duration was recorded. A 10-ml sample was collected from the drained effluent, which was immediately stored at −70 °C for determination of the concentrations of cytokines. A standard peritoneal equilibration test (PET) [25] was initiated for each enrolled patient. A whole blood sample was collected at 120 min and the serum was separated and stored at −70 °C. Residual renal function (RRF) was assessed as the average of urea and creatinine clearance from a 24-h urine collection. Urea clearance index (Kt/V urea) was derived from the collection of the 24-h PD effluent and 24-h urine. We also measured laboratory parameters of each patient including hemoglobin, serum albumin, and high-sensitivity C-reactive protein (hs-CRP).

Evaluation of peritoneal small-solute transport rate and peritoneal protein clearance
Mass transfer area coefficient for creatinine (MTACcr) was calculated using the simplified Garred equation [26]:
\[
\text{MTAC (ml/min)} = \frac{(\text{Vd} \cdot \text{t})}{\ln \left( \frac{\text{Vd}}{\text{P}} \right)}
\]
where Vd is the drained volume, t is the dwell time (240 min), Vi is the instilled dialysate volume, P is the plasma concentration, and Dt is the dialysate concentration at the end of dwell time, normally determined in the dialysate after drainage. The 4-h ultrafiltration (4 h UF) during PET and 24-h ultrafiltration of each patient were assessed.

Peritoneal dialysate protein losses were calculated from the collection of 24-h peritoneal dialysate effluent
by the Biuret method. A validated correction factor was used for the calculation of Prcl [10]: 24-h dialysate protein loss/(serum albumin/0.4783). Prcl was expressed as ml of plasma cleared per day.

Assessment of markers of inflammation and angiogenesis

The concentrations of inflammatory and angiogenic makers in the serum and overnight effluent were determined using the ELISA technique. All samples were run simultaneously for each mediator to avoid intra- and inter-assay variations. Ang-1, Ang2, sTie-2 and VEGF levels were measured using commercially available Quantikine® ELISA kits (R&D Systems Inc., Minneapolis, MN, USA) according to the manufacturer’s instructions. IL-6 and IL-10 concentrations were determined by Human IL-6 ELISA Ready-SET-Go! (eBioscience) and Human IL-10 ELISA Ready-SET-Go! (eBioscience) respectively. Due to the concentrations of dialysate cytokines were influenced by ultrafiltration volume which was affected by peritoneal solute transport rate and dwell time, the dialysate appearance rate (AR) was calculated as dialysate concentration times the drained volume divided by the dwell time and expressed as picograms or nanograms per minute.

Statistical analyses

Data were subjected to the Kolmogorov-Smirnov test to examine their distribution. Continuous variables were presented as mean ± SD or median and inter quartile range (IQR), depending on their distribution. Categorical data were expressed as proportions. Correlations between variables were assessed by the Pearson’s or Spearman rank correlation analyses depending on data distribution. Multivariate regression analysis was used to assess the predictors for MTACcr and Prcl (dependent variable), respectively. Log (base 10)- transfer was applied to non-normally distributed values before regression analysis. Statistical significance was accepted at a two-sided P-value of < 0.05. The analyses were performed using IBM SPSS Statistics software version 21.0.

Results

Patient characteristics

A total of 320 patients were enrolled in present study. Among them, 166 (51.9%) were males with a mean age of 56.8 ± 14.2 years and a median PD duration of 32.5 (9.0–56.3) months. 79(24.7%) patients had diabetes mellitus as comorbidity. The demographic and clinical characteristics of the study are described in Table 1.

Correlation between clinical & biochemical parameters and peritoneal transport characteristics

Significant positive correlations were seen between MTACcr and BSA ($r = 0.25$, $p < 0.001$), systolic blood pressure ($r = 0.153$, $p = 0.007$), PD vintage ($r = 0.162$, $p = 0.003$) as well as historical glucose exposure ($r = 0.121$, $p = 0.030$). In contrast, significant negative correlations were found between MTACcr and serum albumin ($r = -0.232$, $p < 0.001$), 24-h ultrafiltration ($r = -0.2$, $p < 0.001$), as well as 4-h ultrafiltration ($r = -0.317$, $p < 0.001$). Higher Prcl was seen with advanced age ($r = 0.226$, $P < 0.001$), increasing BSA ($r = 0.251$, $p < 0.001$).

### Table 1 Demographic and clinical characteristics of the study subjects (n = 320)

| Variable                  | Value       |
|---------------------------|-------------|
| Age (years)               | 56.8 ± 14.2 |
| Gender (Male)             | 166 (51.9%) |
| BSA (m²)                  | 1.62 ± 0.17 |
| Systolic pressure (mmHg)  | 139 ± 21    |
| Diastolic pressure (mmHg) | 87 ± 13     |
| PD vintage (months)       | 32.5 (9.0–56.3) |
| Underlying renal disease  |             |
| Chronic glomerulonephritis [n (%)] | 165 (51.6%) |
| Diabetic nephropathy [n (%)] | 44 (13.6%)  |
| Hypertension [n (%)]      | 23 (7.2%)   |
| Polycystic kidney disease [n (%)] | 10 (3.1%)  |
| Others [n (%)]            | 49 (15.4%)  |
| Unknown [n (%)]           | 29 (9.1%)   |
| Comorbidity               |             |
| Diabetes mellitus [n (%)] | 79 (24.7%)  |
| Cardiovascular disease [n (%)] | 78 (24.4%)  |
| Number of patients who had peritonitis [n (%)] | 80 (25%)   |
| ACEI/ARB taking [n (%)]   | 188 (58.8%) |
| Historical glucose exposure (g) | 117,720 (37420–249,320) |
| Hemoglobin (g/L)          | 107.1 ± 17.2|
| Serum albumin (g/L)       | 37.0 ± 4.7  |
| hs-CRP (mg/L)             | 2.5 (0.9–6.3) |
| Dialysis adequacy         |             |
| Total Kt/V urea           | 1.96 ± 0.38 |
| Peritoneal Kt/V urea      | 1.56 ± 0.36 |
| Renal Kt/V urea           | 0.24 (0–0.65) |
| RRF (ml/min)              | 0.96 (0–2.88) |
| nPCR (g/Kg/day)           | 0.88 ± 0.19 |
| D/P cr at 4 h             | 0.62 ± 0.11 |
| MTACcr (ml/min)           | 7.64 (5.97–9.56) |
| Prcl (ml/d)               | 69.70 (52.31–90.23) |

Values are expressed as mean ± SD or median (IQR) for continuous data and number of patients (percent) for categorical data. BSA body surface area, ACEI/ARB Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker, hs-CRP high sensitivity C-reactive protein, D/P cr dialysate/plasma creatinine ratio, RRF residual glomerular filtration rate, nPCR normalized protein catabolic rate. MTACcr Mass transfer area coefficient for creatinine, Prcl Peritoneal dialysate protein losses
higher systolic blood pressure ($r = 0.276, P < 0.001$), higher RRF ($r = 0.409, p < 0.001$) and more 24-h urine volume ($r = 0.405, p < 0.001$). The presence of diabetes mellitus and cardiovascular disease were also significantly associated with higher Pcr ($r = 0.187, P = 0.002$ and $r = 0.188, P = 0.002$, respectively). Significant negative correlation was existed between Pcr and serum albumin ($r = −0.497, p < 0.001$), nPCR ($r = −0.207, p = 0.001$) and 4 h-ultrafiltration ($r = −0.133, p = 0.030$).

**Correlation between systemic & dialysate markers and peritoneal transport characteristics**

A significant positive correlation was found between MTACcr and peritoneal protein clearance (Prcr) (Spearman’s rho = 0.326, $P < 0.001$). As shown in Tables 2 and 3, in the overnight effluent, Ang-1AR ($r = −0.201, P < 0.001$) was inversely correlated with both MTACcr, while IL-6 AR ($r = 0.190, P = 0.002$) was positively correlated with MTACcr. Ang-2 AR (Spearman’s rho = 0.123, $P = 0.028$) and sTie-2 AR (Spearman’s rho = 0.142, $P = 0.011$) were positively correlated with Prcr, respectively. Serum Ang-1 concentration was inversely correlated with both MTACcr ($r = −0.205, p < 0.001$) and Prcr (Spearman’s rho = −0.203, $P < 0.001$). Serum IL-6 concentration was positively correlated with both MTACcr ($r = 0.173, p = 0.004$) and Prcr (Spearman’s rho = 0.136, $p = 0.016$).

**Correlation between systemic markers and dialysate markers**

Serum Ang-1, Ang-2 and sTie-2 levels in this cohort were 42,015.00 (27,810.00–63,320.00) pg/ml, 5451.43 (3429.99–7740.90) pg/ml, and 20.13 (15.36–25.49) ng/ml, respectively. Serum IL-6, IL-10 and VEGF concentrations were 5.56 (1.88–13.62) pg/ml, 1.38 (0.99–2.02) pg/ml, 26.94 (14.42–46.70) pg/ml, respectively. Ang-1, Ang-2, sTie-2, IL-6, IL-10 and VEGF levels in PDF in this cohort were 130.09 (70.42–266.78) pg/ml, 300.14 (170.69–464.93) pg/ml, 0.15 (0.11–0.24) ng/ml, 17.79 (10.35–33.81) pg/ml, 1.48 (0.79–2.74) pg/ml, and 28.03 (18.26–49.18) pg/ml, respectively. The serum to dialysate concentration ratios of Ang-1, Ang-2, sTie-2, IL-6, IL-10 and VEGF are 269.44, 18.97, 119.92, 0.29, 0.93 and 0.95, respectively. There was a significant positive correlation between the systemic and dialysate concentrations of Ang-1 ($r = 0.180, P < 0.01$), Ang-2 ($r = 0.398, P < 0.01$) and sTie-2 ($r = 0.259, P < 0.01$), respectively. However, no correlations of IL-6 ($r = 0.038, P = 0.530$), IL-10 ($r = 0.007, P = 0.897$) and VEGF ($r = 0.084, P = 0.132$) were found between their systemic and dialysate concentrations (Fig. 1).

**Independent associated factors of MTACcr and Prcr**

To analyze the independent contributions of various cytokines to the variance of MTACcr and Prcr, we performed a series of multiple regression models. After adjustment for age, sex, diabetes mellitus, BSA, PD vintage, history glucose exposure, nPCR and RRF, serum IL-6 ($\beta = 0.105$ (0.011–0.197), $P = 0.028$) and serum Ang-1 ($\beta = −0.122$ (−0.217–−0.026), $P = 0.012$) were independently associated with MTACcr in the Model2; dialysate IL-6 AR ($\beta = 0.130$ (0.061–0.199), $P = 0.01$) and dialysate Ang-1 AR ($\beta = −0.082$ (−0.157–−0.007), $P = 0.032$) were independently associated with MTACcr in the Model3 (Table 4). However, after adjustment for age, sex, diabetes mellitus, BSA, PD vintage, history glucose exposure, nPCR and RRF, serum IL-6 ($\beta = 0.048$ (0.019–0.077), $P = 0.001$) and serum Ang-1 ($\beta = −0.068$ (−0.127–−0.010), $P = 0.003$) were independently associated with Prcl (Table 5). When including both serum and dialysate markers in a single model (Model4), BSA ($\beta = 0.0243$ (0.0114,0.0371), $P = 0.01$), history glucose exposure ($\beta = 0.055$ (0.020, 0.140), $P < 0.01$), dialysate IL-6 AR ($\beta = 0.083$ (0.027, 0.139), $P < 0.01$) and dialysate Ang-1 AR ($\beta = −0.069$ (−0.118, −0.019), $P < 0.01$) were independent associated factors of MTACcr; however, only BSA($\beta = 0.058$ (0.036–0.079), $P < 0.01$) and serum Ang-1 ($\beta = −0.040$ (−0.067, −0.013), $P < 0.01$) were independent associated factors of Prcr.

**Discussion**

Our results showed that BSA, history glucose exposure, dialysate IL-6 AR and dialysate Ang-1 AR were independent associated factors of MTACcr, while BSA and serum Ang-1 were independently associated with Prcr, suggesting that peritoneal small-solute transport and peritoneal large molecular transport may be affected by slightly different panels of inflammatory and angiogenic factors.

During long-term PD, the peritoneal membrane undergoes both structural and functional alterations [2]. The structural changes include denudation of the

| Table 2 Correlation between serum markers and peritoneal transport characteristics | Log MTACcr | Log Ang-1 | Log Ang-2 | Log sTie-2 | Log IL-6 | Log IL-10 | Log VEGF |
|--------------------------------|----------|-----------|-----------|-----------|---------|----------|---------|
| Log MTACcr | r          | −0.205    | 0.101     | −0.054    | 0.173   | −0.021   | −0.105  |
|            | p          | < 0.001   | 0.076     | 0.337     | 0.004   | 0.709    | 0.064   |
| Log Prcr   | rho        | −0.203    | 0.046     | −0.006    | 0.136   | −0.047   | 0.001   |
|            | p          | < 0.001   | 0.408     | 0.919     | 0.016   | 0.407    | 0.990   |
mesothelial cell layer, thickening of the sub-mesothelial space, neoangiogenesis, and thickening of the vascular wall by type IV collagen deposition [27]. In parallel with these alterations, the most common functional alteration during long-term PD is increased peritoneal small-solute transport rate [3, 4], which may impair ultrafiltration capacity [5]. In our previous study, we reported that MTACcr increased significantly over time while ultrafiltration capacity decreased [28]. High peritoneal small-solute transport rate has been recognized to be an independent risk factor for mortality and technique failure in PD patients [6-8]. A meta-analysis including 6648 PD patients showed that a higher peritoneal small-solute transport rate was associated with a significantly higher mortality and a trend of higher technique failure: 19 studies were pooled to generate a summary mortality relative risk of 1.15 for every 0.1 increase in the D/Pcr [7]. These studies suggested the close association of increased peritoneal small-solute transport with poor outcomes in PD patients.

Table 3 Correlation between effluent markers and peritoneal transport characteristics

|                  | LogAng-1 AR | LogAng-2 AR | Log sTie-2 AR | Log IL-6 AR | Log IL-10 AR | Log VEGF AR |
|------------------|-------------|-------------|---------------|-------------|--------------|-------------|
| LogMTACcr r      | -0.201      | -0.054      | -0.021        | 0.167       | -0.094       | -0.053      |
| p                | < 0.001     | 0.342       | 0.704         | 0.003       | 0.097        | 0.351       |
| LogPrcl rho      | 0.032       | 0.123       | 0.142         | 0.093       | 0.097        | 0.034       |
| p                | 0.574       | 0.028       | 0.011         | 0.10        | 0.085        | 0.542       |

Shi et al. BMC Nephrology (2018) 19:119

Fig. 1 Correlation between systemic and dialysate levels of Ang-1 (a), Ang-2 (b), sTie-2 (c), IL-6 (d), IL-10 (e) and VEGF (f), respectively
Peritoneal protein clearance (PrCl) in PD patients mainly reflects protein leakage across the large pores, which is equivalent to large-pore flow (JvL). It has been shown that patients starting PD with active CVD had higher protein and albumin levels in their peritoneal effluent, and cardiovascular events were more frequent in patients with greater peritoneal albumin losses [12]. Heaf et al. [31] or tumor necrosis factor-α [32], both frequently observed in PD patients. A balanced Ang-1/Ang-2 ratio is required for maintaining the normal function of the endothelial layer [15]. It has been shown [33] in atherosclerotic plaques with high microvesSEL density that the local balance between Ang-1 and Ang-2 was in favor of Ang-2. In present study, we found that dialysate Ang-1 level was independently associated with MTACcr, while serum Ang-1 level was independently associated with PrCl. Based on the three-pore model of Rippe and colleagues [34], solute and water transport occurs through three types of pores located in the peritoneal capillary endothelium. Lower Ang-1 level, resulting in a disbalanced Ang-1/Ang-2 ratio in favor of Ang-2, might be closely linked to angiogenesis in the local peritoneal cavity. Increased peritoneal vascular surface area, such as angiogenesis, mainly resulting in a larger small pore area might contribute to increased MTACcr. This might be the reason for dialysate Ang-1 level negatively correlating with MTACcr. However, peritoneal protein leakage actually depended on

### Table 4 Multiple regression models for MTACcr (ml/min) in PD patients

| Model   | β (95% CI) | r² (Model) |
|---------|------------|------------|
| Model 1 | (β, 95% CI) | (r² = 0.35) |
| Age (years) | 0.013 (–0.208–0.042) | 0.005 (–0.001–0.018) | 0.006 (–0.005–0.004) | 0.002 (–0.005–0.003) |
| Sex (males %) | 0.054 (–0.408–0.517) | 0.014 (–0.099–0.128) | 0.015 (–0.046–0.118) | 0.006 (–0.092–0.265) |
| DM | –0.026 (–1.060–0.008) | –0.028 (–0.062–0.006) | –0.093 (–0.177–0.112) | –0.033 (–1.535–0.879) |
| BSA (m²) | 0.094 (0.042–0.145) | 0.052 (0.019–0.085) | 0.082 (0.031–0.132) | 0.0243 (0.0114, 0.0371) |
| PD vintage(months) | 0.042 (–0.148–0.157) | 0.004 (–0.036–0.043) | 0.003 (–0.037–0.042) | 0.007 (–0.003–0.027) |
| Historical glucose exposure(g) | 0.110 (0.073–0.349) | 0.095 (0.027–0.531) | 0.0861 (0.024–0.420) | 0.055 (0.020, 0.140) |
| nPCR(g/Kg/day) | –0.034 (–0.118–0.051) | –0.106 (–0.408–0.028) | –0.107 (–0.401–0.099) | –0.051 (–0.449–0.972) |
| RRF(ml/min) | 0.006 (–0.006–0.018) | 0.146 (–0.276–0.567) | 0.093 (–0.305–0.492) | 0.069 (–0.167–0.443) |
| Log serum IL-6 | 0.105 (0.011–0.197) | 0.001 (–0.006–0.008) | 0.0013 (–0.013–0.051) |
| Log serum IL-10 | –0.004 (–0.025–0.018) | 0.003 (–0.005–0.111) |
| Log serum VEGF | 0.018 (–0.010–0.045) | 0.005 (–0.075–0.045) |
| Log serum Ang-1 | –0.122 (–0.217–0.026) | –0.005 (–0.064–0.051) |
| Log serum Ang-2 | 0.032 (–0.024–0.089) | 0.004 (–0.008–0.005) |
| Log serum sTie-2 | 0.030 (–0.026–0.086) | 0.130 (0.061–0.199) | 0.083 (0.027, 0.139) |
| Log dialysate IL-6 AR | –0.112 (–0.187–0.036) | 0.001 (–0.037–0.013) |
| Log dialysate IL-10 AR | –0.002 (–0.005–0.018) | –0.001 (–0.021–0.018) |
| Log dialysate Ang-1 AR | –0.082 (–0.157–0.007) | –0.069 (–0.118, –0.019) |
| Log dialysate Ang-2 AR | 0.013 (–0.002–0.028) | 0.002 (–0.003–0.003) |
| Log dialysate sTie-2 AR | 0.086 (–0.006–0.178) | 0.003 (–0.008–0.005) |
large-pore transport which is much few. Prcl might be more closely correlated with systemic microvascular endothelial layer hyperpermeability, resulted mainly from circulating endothelial integrity impairment and larger inter-endothelial gaps. Recent studies have also shown that systemic Ang-1 could prevent the permeability effects of VEGF by stabilizing the pericyte-endothelial cell association and strengthening inter-endothelial junctions [35, 36]. Thus, decreased serum Ang-1 levels or lower serum Ang-1/Ang2 ratio might be involved in greater peritoneal protein loss.

We found that peritoneal glucose exposure was independently associated with MTAccr. It is well known that long-term success of PD depends mainly on the ability of the peritoneal membrane to provide adequate solute clearances and ultrafiltration. Therefore, with the gradual decline of residual renal function, greater dialysis doses or hypertonic dialysis solution were usually required to maintain the adequate solute removal and euvolemia. However, exposure to hypertonic dialysis solution has long been suspected as a mechanism of peritoneal membrane injury [24]. Glucose was recognized as a strong proinflammatory agent and in a clinical evaluation, Fujimori et al. [37] showed that higher glucose concentration induced higher production of intraperitoneal IL-6. A recent study demonstrated that the use of glucose-based solutions was associated with higher levels of VEGF [38]. Therefore, these studies suggested that glucose could induce local peritoneal inflammation and angiogenesis through direct and indirect effects, consequently resulting in higher MTAccr.

IL-6 has been established to be a central mediator of inflammatory response in the peritoneal cavity and its level increased with therapy duration [39]. Pecoits-Filho et al. [39] found that intraperitoneal and systemic IL-6 and soluble IL-6 receptor (sIL-6R) levels were closely related to peritoneal small-solute transport. However, Lambie et al. [40] showed that local but not systemic inflammation was associated with peritoneal small-solute transport. In present study, we found that dialysate IL-6 levels were independent risk factors contributing to higher MTAccr. Oh et al. [41] recently reported that intraperitoneal IL-6 level was significantly associated with inflammatory and angiogenic factors, such as MCP-1, VEGF and Ang-2. These studies suggested that IL-6 might directly promote or indirectly mediate angiogenesis, which in turn lead to an increased peritoneal vascular surface area and a larger small pore area in the local peritoneal cavity. This might be the reason for intraperitoneal IL-6 levels associated with MTAccr. In addition, we found that

Table 5 Multiple regression models for Prcl (ml/d) in PD patients

|                        | Model 1 (β, 95% CI) | Model 2 (β, 95% CI) | Model 3 (β, 95% CI) | Model 4 (β, 95% CI) |
|------------------------|---------------------|---------------------|---------------------|---------------------|
| Age (years)            | 0.035 (−0.035−0.105) | 0.022 (−0.046−0.090) | 0.016 (−0.042−0.074) | 0.005 (−0.006−0.016) |
| Sex (males %)          | −0.052 (−0.121−0.017) | −0.065 (−0.330−0.199) | −0.029 (−0.087−0.030) | −0.001 (−0.017−0.043) |
| DM                     | 0.040 (0.022−0.058)  | 0.016 (−0.034−0.066)  | 0.0171 (−0.01−0.044) | 0.007 (−0.015−0.032)  |
| BSA (m²)               | 0.217 (0.044−0.429)  | 0.156 (0.052−0.482)  | 0.171 (0.041−0.506)  | 0.058 (0.036−0.079)   |
| PD vintage (months)    | 0.103 (−0.106−0.413) | 0.053 (−0.017−0.123) | 0.091 (−0.067−0.086) | 0.002 (−0.001−0.007)  |
| Historical glucose exposure (g) | 0.041 (−0.035−0.102) | 0.008 (−0.042−0.070) | 0.006 (−0.047−0.120) | 0.001 (−0.007−0.003)  |
| nPCR (g/Kg/day)        | −0.177 (−0.346−−0.001) | −0.105 (−0.047−0.070) | −0.105 (−0.035−0.002) | −0.103 (−0.357−0.139) |
| RRF (ml/min)           | 0.041 (−0.030−0.113)  | 0.019 (−0.052−0.070)  | 0.017 (−0.054−0.078) | 0.003 (−0.005−0.011)  |
| Log serum IL-6         | 0.048 (0.019−0.077)  | 0.004 (−0.050−0.059)  | 0.003 (−0.009−0.032) |                       |
| Log serum IL-10        | −0.008 (−0.010−0.044) |                       | −0.002 (−0.008−0.004) |                       |
| Log serum VEGF         | 0.005 (−0.025−0.018)  |                       | −0.040 (−0.067−0.013) |                       |
| Log serum Ang-1        | −0.068 (−0.127−0.010) |                       | −0.001 (−0.001−0.002) |                       |
| Log serum Ang-2        | 0.016 (−0.034−0.066)  |                       | −0.002 (−0.002−0.001) |                       |
| Log serum sTie-2       | −0.001 (−0.026−0.086) |                       | −0.002 (−0.002−0.001) |                       |
| Log dialysate IL-6 AR  | 0.086 (−0.006−0.188)  | 0.004 (−0.005−0.009)  |                       |                       |
| Log dialysate IL-10 AR | −0.046 (−0.077−0.013) | −0.002 (−0.008−0.004) |                       |                       |
| Log dialysate VEGF AR  | −0.020 (−0.046−0.005) | −0.009 (−0.012−0.001) |                       |                       |
| Log dialysate Ang-1 AR | 0.100 (−0.013−0.067)  | 0.009 (−0.004−0.042)  |                       |                       |
| Log dialysate Ang-2 AR | 0.036 (−0.001−0.072)  | 0.004 (−0.008−0.00)   |                       |                       |
| Log dialysate sTie-2 AR | 0.025 (−0.014−0.064)  | −0.002 (−0.008−0.004) |                       |                       |

r² = 0.37
r² = 0.59
r² = 0.38
r² = 0.48
dialysate IL-6 level was not an independent risk factor affecting Prcl. It has been reported that peritoneal protein leakage actually depended on peritoneal large-pore transport, which was, for the most part, correlated with systemic endothelial dysfunction [13, 29]. Protein leak across large pores was increased during systemic vascular or by increased hydrostatic pressure across the capillary [42]. Thus, Prcl may serve as a marker for the severity of systemic vascular disease and injury. Clearly further studies are needed to investigate the underlying mechanism.

In parallel with previous reports [39, 43, 44], we found that the dialysate concentrations of IL-6, IL-10 and VEGF were higher than their serum counterparts, respectively. This suggested the local production of these molecules in the peritoneal cavity, reflecting chronic inflammatory state of the peritoneum apart from the systemic inflammation. Unlike the aforementioned molecules analyzed in our study, serum concentrations of Ang-1 and sTie-2 were > 100 times higher than their dialysate concentrations and serum concentration of Ang-2 was almost 20 times higher than its dialysate counterpart. So it was reasonable, with such remarkable concentration gradients, that the intraperitoneal concentrations of these molecules were more heavily dependent on their transport from the systemic circulation rather than the local production in the peritoneum.

Our study has several limitations. This was a single center study; however, we have detailed information about patients’ characteristics and laboratory data, and the same doctors and nurses took care of all patients thereby avoiding potential confounders of different centers. Secondly, both incident and prevalent patients were investigated. Thirdly, the study was cross-sectional in nature and the cytokines levels were measured once at enrollment. The effect of time-average cytokines levels might be underestimated. Besides, since there is a lot of possible underlying mechanisms and causative correlations, it is difficult to draw such function disturbances based upon only one measurement of cytokines, and clearly more time depended measurements are required. Further prospective follow-up studies of these patients are needed to elucidate the cause and effect relationships between these associated cytokines and peritoneal transport rate of small molecules and macromolecules.

Conclusion
Our study indicated that BSA, history glucose exposure, dialysate IL-6 AR and dialysate Ang-1 AR were independent associated factors of MTACcr, while BSA and serum Ang-1 levels were independently associated with Prcl. These results suggested that peritoneal small solute transport and peritoneal large molecular transport might be affected by slightly different panels of inflammatory and angiogenic factors.

Abbreviations
ACEi/ARB: Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker; Ang-1: Angiopoietin-1; Ang-2: Angiopoietin-2; AR: The dialysate appearance rate; BSA: Body surface area; CAPD: Chronic ambulatory peritoneal dialysis; CVD: Cardiovascular disease; D/P cr: Dialysate/Plasma creatinine ratio; DM: Diabetes mellitus; Kt/V urea: Urea clearance index; MTACcr: Mass transfer area coefficient of creatinine; nPCR: Normalized protein catabolic rate; PD: Peritoneal dialysis; PET: Peritoneal equilibration test; Prcl: Peritoneal protein clearance; RRF: Residual glomerular filtration rate; sTie-2: Soluble Tie-2; VEGF: Vascular endothelial growth factor

Funding
This study was supported by grants from National Natural Science Foundation of China (30600290, 81370864, 81670691) and Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20152211).

Availability of data and materials
All data generated or analyzed during this study are included in this published article. The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
SY: study design, data collection, data analysis, drafting the article, YH: data collection, YJ: data collection, ZH: data collection, HJ: data collection, SY: study design, data collection, data analysis, drafting the article, YH: data collection, NZ: guidance and support, QJ: guidance and support, FW: study design, data analysis, statistics and critical revision of the paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China (number: [2013] N022; year:January/2014). Written consent was given by the patients for their information to be stored in the hospital database and used for research.

Consent for publication
Each patient gave his/her consent to publish the individual results obtained.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 26 July 2016 Accepted: 15 May 2018
Published online: 23 May 2018

References
1. Grassmann A, Giebberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005;20(12):2587–93.
2. Schilte MN, Celle JW, Wee PM, Beelen RH, Van den Born J. Factors contributing to peritoneal tissue remodelling in peritoneal dialysis. Perit Dial Int. 2009/29:605–17.
3. Hung KY, Huang JW, Tsai TJ, Chen WY. Natural changes in peritoneal equilibration test results in continuous ambulatory peritoneal dialysis patients: a retrospective, seven year cohort survey. Artif Organs. 2000;24: 261–4.
4. Wang T, Heimbürger O, Waniek J, Bergström J, Lindholm B. Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients. Nephrol Dial Transplant. 1998;13:1242–9.
5. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int. 2000;56: 2437–45.
6. Chung SH, Heimbürger O, Lindholm B. Poor outcomes for fast transporters on PD: the rise and fall of a clinical concern. Semin Dial. 2008;21:7–10.
7. Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol. 2006;17:2591–8.
8. Rumpsfeld M, McDonald SP, Johnson DW. Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol. 2006;17:271–8.

9. Heaf J. Pathogenic effects of a high peritoneal transport rate. Semin. Dial. 2000;13:188–93.

10. Krediet RT, Zuyderhoudt FM, Boeschoten EW, Aziz L. Peritoneal permeability to proteins in diabetic and non-diabetic continuous ambulatory peritoneal dialysis patients. Nephron. 1986;42:133–40.

11. Sánchez-Villanueva R, Bajo A, Del Peso G, Fernandez-Reyes MJ, González E, Romero S, et al. Higher daily peritoneal protein clearance when initiating peritoneal dialysis is independently associated with peripheral arterial disease (PAD): a possible new marker of systemic endothelial dysfunction? Nephrol Dial Transplant. 2009;24:1009–14.

12. Szteto CC, Chow KM, Lam CW, Cheung R, Kwan BC, Chung KY, et al. Peritoneal albumin excretion is a strong predictor of cardiovascular events in peritoneal dialysis patients: a prospective cohort study. Perit Dial Int. 2005;25:445–52.

13. Dong J, Chen Y, Luo S, Xu R, Xu Y. Peritoneal protein leakage, systemic inflammation, and peritonitis risk in patients on peritoneal dialysis. Perit Dial Int. 2013;33(3):273–9.

14. Perl J, Huckvale K, Chellar M, John B, Davies SJ. Peritoneal protein clearance and not peritoneal membrane transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol. 2009;4:1201–7.

15. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and vascular protection. Circ Res. 2006;98:1014–22.

16. Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/ dysfunction and atherosclerosis. Atherosclerosis. 2005;180:113–8.

17. Wang Y, Pampou S, Fujikawa K, Varticovski L. Opposing effect of angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvesel density. J Vasc Res. 2008;45:244–50.

18. Yeo D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino L, et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of sMrNA. J Biol Chem. 2007;282:31038–45.

19. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235–9.

20. Post S, Peeters W, Busser E. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvesel density. J Vasc Res. 2008;45:244–50.

21. Tashiro K, Tomii Y, Nakamura R, Shi Y, Araki T, Watanabe M, et al. Stabilization of breast cancer xenograft tumour neoangiogenesis by angiopoietin-1. British Journal of Cancer. 2002;86:645–51.

22. Lee SW, Kim WJ, Sun HO, Choi YK, Kim KW. Angiopoietin-1 reduces vascular endothelial growth factor-induced brain endothelial permeability via upregulation of ZO-2. Int J Mol Med. 2009;23:279–84.

23. Fujiwara A, Naito H, Miyazaki T, Azuma M, Hashimoto S, Horikawa S, et al. Blood vessel formation in vivo is suppressed by expressing angiopoietin-1 in transgenic mice. Circ Res. 2006;98:1014–22.

24. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and systemic lupus erythematosus. Ann Rheum Dis. 2008;67:1638–43.

25. Yoon MO, Song A, Lee H, Ro H, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med. 2006;3(3):e46.

26. Krediet RT, Boeschoten EW, Zuyderhoudt FM, Strackee J, Arisz L. Simple method for evaluating glucose transport across the peritoneal membrane during CAPD according to the three-pore model. Perit Dial Int. 2004;24:10–27.

27. Tian S, Hayes AJ, Metheny-Barlow LJ, Li LY. Stabilization of breast cancer xenograft tumour neoangiogenesis by angiopoietin-1. British Journal of Cancer. 2002;86:645–51.

28. Yang X, Zhang H, Hang Y, Yan H, Lin A, Fang W, et al. Intraperitoneal glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of sMrNA. J Biol Chem. 2007;282:31038–45.

29. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235–9.

30. Post S, Peeters W, Busser E. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvesel density. J Vasc Res. 2008;45:244–50.